1
Colandrea Vincent J, Doherty George A, Hale Jeffrey J, Lynch Christopher, Mills Sander G, Neway William Edward Iii, Toth Leslie: 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists. Merck & Co, Colandrea Vincent J, Doherty George A, Hale Jeffrey J, Lynch Christopher, Mills Sander G, Neway William Edward Iii, Toth Leslie, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, December 2, 2004: WO/2004/103279 (94 worldwide citation)

The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of ...


2
Dorn Conrad P, Hale Jeffrey J, Maccoss Malcolm, Mills Sander G, Ladduwahetty Tamara, Shah Shrenik K: Morpholine and thiomorpholine tachykinin receptor antagonists.. Merck & Co, January 5, 1994: EP0577394-A1 (78 worldwide citation)

Substituted heterocycles of the general structural formula: are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.


3
Jones Todd K, Askin David, Mills Sander G, Reamer Robert A, Desmond Richard, Volante Ralph P, Tschaen David M, Shinkai Ichiro: Process for synthesis of fk-506 and tricarbonyl intermediates.. Merck & Co, July 18, 1990: EP0378318-A1 (43 worldwide citation)

A process is described for the total synthesis of the macrolide immunosuppressant, FK-506, and important tricarbonyl process intermediates thereof. The tricarbonyl intermediates can be produced by the mild oxidation of 2,3-dihydroxy carboxylate compounds containing olefin moieties.


4
Butora Gabor, Guiadeen Deodialsingh, Kothandaraman Shankaran, Maccoss Malcolm, Mills Sander G, Yang Lihu: Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity. Merck & Co, Butora Gabor, Guiadeen Deodialsingh, Kothandaraman Shankaran, Maccoss Malcolm, Mills Sander G, Yang Lihu, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, August 11, 2005: WO/2005/072361 (38 worldwide citation)

Compounds of Formula I and Formula II (wherein A, E, j, k, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the preven ...


5
Devita Robert J, Mills Sander G, Young Jonathan R, Lin Peter: Phenyl pyrrolidine ether tachykinin receptor antagonists. Merck & Co, Devita Robert J, Mills Sander G, Young Jonathan R, Lin Peter, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, April 14, 2005: WO/2005/032464 (17 worldwide citation)

The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as act ...


6
Doherty George A, Hale Jeffrey J, Mills Sander G: (amino)Indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles. Merck & Co, Doherty George A, Hale Jeffrey J, Mills Sander G, sMERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, July 15, 2004: WO/2004/058149 (16 worldwide citation)

The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions an ...


7
Butora Gabor, Mills Sander G, Pasternak Alexander, Shankaran Kothandaraman, Yang Lihu, Zhou Changyou, Goble Stephen D: Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity. Merck & Co, Butora Gabor, Mills Sander G, Pasternak Alexander, Shankaran Kothandaraman, Yang Lihu, Zhou Changyou, Goble Stephen D, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, May 21, 2004: WO/2004/041161 (16 worldwide citation)

The present invention is directed to compounds of the formula (I) (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R27, R28, R29, R30, R31, X, m, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful a ...


8
Ge Min, Cline Eric, Yang Lihu, Mills Sander G: Substituted pyrazoles as ghrelin receptor antagonists. Merck & Co, Ge Min, Cline Eric, Yang Lihu, Mills Sander G, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, January 17, 2008: WO/2008/008286 (16 worldwide citation)

Certain novel N-acylated spiropiperidine derivatives are ligands of the human ghrelin receptor(s) and, in particular, are antagonists/inverse agonists of the human ghrelin receptor. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modula ...


9
Yang Lihu, Mills Sander G, Zhou Changyou, Goble Stephen D, Pasternak Alexander: 2,6-disubstituted piperidines as modulators of chemokine receptor activity. Merck & Co, Yang Lihu, Mills Sander G, Zhou Changyou, Goble Stephen D, Pasternak Alexander, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, August 4, 2005: WO/2005/070133 (13 worldwide citation)

The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammator ...


10
Goble Stephen D, Pasternak Alexander, Mills Sander G, Zhou Changyou, Yang Lihu: Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity. Merck & Co, Goble Stephen D, Pasternak Alexander, Mills Sander G, Zhou Changyou, Yang Lihu, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, September 30, 2004: WO/2004/082616 (12 worldwide citation)

The present invention is directed to compounds of the formula (I) Wherein A, B, D, X, Y, n, R1, R3, R4, R5, R15, R16, R17, R18 and the dashed line are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemo ...